Health Costs

In his latest column for The Wall Street Journal’s Think Tank, Drew Altman examines the public’s mixed views about prescription drug ads and their impact on prescribing patterns, based on a new Kaiser Family Foundation survey. All previous columns by Drew Altman are available online.

In his latest column for The Wall Street Journal’s Think Tank, Drew Altman explores the data behind public concern about prescription drug costs and highlights that the people most in need are the most burdened by the problem. All previous columns by Drew Altman are online.

In his latest column for The Wall Street Journal’s Think Tank, Drew Altman examines the problems many Americans with health insurance are having paying medical bills based on a new Kaiser-New York Times Survey, and discusses why the issue of the adequacy of insurance coverage is gaining traction. All previous columns…

This Visualizing Health Policy infographic provides details on cancer spending and outcomes in the United States.

This Visualizing Health Policy infographic provides details on cancer spending and outcomes in the United States. The U.S. cancer mortality rate, 203 deaths per 100,000 population, was slightly lower than in comparable countries in 2010. Among cancers, lung cancer is the largest contributor to disease burden for both men and…

Using Medicaid State Drug Utilization Data, this brief presents the 50 most costly drugs before rebates used by the Medicaid program over the January 2014 through June 2015 period. It then examines reasons why these drugs are so costly; explores case studies on opioids, hepatitis C drugs, and the drug Abilify; and considers policy implications.

The Kaiser Family Foundation will host a web conversation to discuss the drivers of recent and forecasted trends in prescription drug spending and examine how drug prices are set.